Intratonsillar immunotherapy for allergic rhinitis treatment

Inclusion Criteria:

* Voluntarily sign informed consent.
* Commitment to follow the research procedures and cooperate with the implementation of the entire research process.
* Diagnosis in accordance with ARIA guidelines, based on:

  ① Symptoms: Two or more symptoms such as paroxysmal sneezing, watery nose, nasal itching, and nasal congestion, with symptoms lasting or accumulating for more than 1 hour per day. May be accompanied by eye symptoms such as tearing, eye itching, and eye redness.

  ② Signs: Common nasal mucosa pale, edema, nasal watery secretions.
  * Allergen test: Positive for skin prick test (SPT) and/or serum-specific IgE for at least one allergen, or positive for nasal provocation test.
* Have a history of allergic rhinitis caused by atopic allergens and one of the following:

  ① No significant relief after drug treatment.

  ② Do not want to continue taking medication for a long time.

  ③ Long-term drug treatment can produce adverse side effects.
  * Allergens cannot be effectively avoided in daily life.
* Women of childbearing age must ensure that they do not become pregnant during the treatment cycle.
* Must be between 5 and 65 years old.

Exclusion Criteria:

* Allergic to the excipient (aluminum hydroxide) of Allergopharma or the rescue medication epinephrine.
* Respiratory disease other than stable asthma.
* Pulmonary insufficiency (NYHA grade II and above or FEV1 \< 80%) or irreversible changes in the responding organs such as emphysema and bronchiectasis.
* Severe acute or chronic diseases (including malignant diseases), inflammation, and fever.
* Multiple sclerosis.
* Immune system diseases (autoimmune diseases, immune diseases caused by antigen and antibody complexes, immune deficiencies, etc.).
* Active tuberculosis.
* Severe mental disorder.
* Obvious cardiac insufficiency.
* A history of severe recurrent acute sinusitis (defined as two episodes per year within the past 2 years, each requiring antibiotic treatment).
* A history of chronic sinusitis, including at least two of the following symptoms (at least one of which should be nasal congestion or runny nose):

  ① Nasal congestion, runny nose, facial pressure, or pain.

  ② Having a diminished or lost sense of smell.

  ③ Endoscopic or CT examination showed signs of sinusitis.
* Severe liver and renal impairment, including but not limited to abnormal liver function (such as ALT, AST elevation more than 2 times the normal range), abnormal kidney function (such as creatinine clearance less than 60 mL/min), etc.
* Smokers averaging more than 5 cigarettes per day in the 3 months prior to the trial or unable to give up smoking during the entire hospital stay.
* Regular drinkers in the 3 months prior to the trial, i.e., more than 2 units of alcohol per day on average (1 unit = 360ml beer or 45ml spirits with 40% alcohol or 150ml wine).
* Received immunotherapy within the last 3 years (subcutaneous injection or sublingual allergen-specific immunotherapy, etc.).
* Patients who used experimental drugs or participated in other clinical studies within 30 days prior to treatment.
* Patients treated with IgE monoclonal antibodies within the last 4 months.
* Patients who are taking beta blockers.
* Patients who do not have sufficient knowledge about the trial.
* Not between the ages of 5 and 65.
* Patients who are pregnant or nursing during the study period, or who plan to become pregnant.
* Patients who are unable to have tonsil injections due to chronic tonsillitis, small tonsils, prior tonsillectomy, etc.